Value-creating divestment supports OncoVision focus on the clinical business while Bruker strengthens its leadership in preclinical imaging
Valencia, Spain – November 22, 2016 – Oncovision a leading manufacturer of medical imaging devices, today announced that it has closed the sale of its preclinical PET Imaging business to Bruker (NASDAQ: BRKR) the leading manufacturer of high-performance scientific research instruments and high-value analytical solutions. Oncovision had previously announced an agreement to sell this business in September 2016. Financial terms were not disclosed.
“I am very pleased that the agreement finally closed thanks to the efforts of a great group of individuals and institutions that have joint their efforts so both companies can reach this agreement. From Oncovision’s side we are very pleased with the outcome and I am confident that both companies can look to a bright future” Ignasi Vivas, CEO of Oncovision, stated.
The agreement reinforces Oncovision’s focus on developing its clinical imaging business in its three main therapy areas of Breast cancer, Melanoma and Alzheimer. The portfolio comprises the approved imaging products Mammi PET, Sentinella and W-Probe, while CareMiBrain is in clinical development.
Ignasi Vivas, CEO at Oncovision, said: “This agreement reinforces our strategic focus to invest in our three main therapy areas where we can make the greatest difference to patients’ lives. We’re pleased that our Albira technology line of products will continue to serve a critical research need through Bruker’s dedicated focus on pre-clinical business, ensuring these important imaging technologies reach greater numbers of customers around the world.”
Dr. Wulf I. Jung, President of Bruker’s Preclinical Imaging Division, stated: “PET imaging is one
of the most important imaging modalities for translational research. With this acquisition, Bruker is strengthening its leadership in preclinical imaging”
Frank H. Laukien, Ph.D., President and CEO of Bruker Corporation, commented: “Bruke continues to invest and position itself for sustainable growth in the important preclinial imaging market. We are very pleased with this advanced technology acquisition, and believe that our unique PET/MRI and PET/SPECT/CT systems will significantly advance quantitative, highest resolution PET translational research.”